Bio‑Rad Posts GAAP Loss on Equity Write‑Down, Lowers 2026 Outlook Amid Modest Sales Gains

Bio‑Rad’s first‑quarter results showed a mixed picture of operational resilience and accounting turbulence. Net sales reached $592.1 million, a modest 1.1% increase from the same quarter a year earlier, but on a currency‑neutral basis revenue actually fell 4.2%. The Life Science segment was essentially flat at $228.5 million, while Clinical Diagnostics grew 1.9% to $363.6 million. Both segments, however, posted currency‑adjusted declines of roughly 4% as a weaker U.S. dollar and regional headwinds weighed on performance.

The headline loss is almost entirely attributable to a $738 million unrealized loss on Bio‑Rad’s investment in Sartorius AG, a German life‑science equipment maker. This non‑operating charge pushed GAAP earnings to a negative $527 million, or $19.55 per diluted share, compared with a $64 million profit a year ago. Excluding that item, the company posted a non‑GAAP profit of $50.9 million, or $1.89 per share, and generated $78 million of free cash flow. Management therefore emphasized the underlying cash‑generation strength despite the accounting hit.

Operating cash flow remained healthy at $108 million, though it slipped from $130 million a year earlier. The firm used $78 million of free cash flow to repurchase roughly 176 thousand shares, signaling confidence in its balance sheet. Total cash and short‑term investments sit at $1.57 billion, while long‑term debt has been trimmed to $803 million, down from $1.2 billion a year ago, improving leverage ratios.

Looking ahead, Bio‑Rad narrowed its 2026 revenue outlook. The company now expects non‑GAAP, currency‑neutral revenue to decline up to 3% or grow as much as 0.5%, versus the prior 0.5%‑1.5% growth range. The operating‑margin target was also lowered to 10%‑12% from 12%‑12.5%. Management cited continued softness in the academic research market in the Americas and the escalation of conflict in the Middle East, which has constrained demand for clinical‑diagnostics consumables.

The market has already priced in some of the uncertainty. Bio‑Rad shares trade at $280.12, down 7.5% year‑to‑date and lagging the S&P 500 by roughly 13% on a total‑return basis. The stock is trading about 18% below its 52‑week high of $343.12 but still 32% above its 52‑week low of $211.43. Relative volume is elevated at 2.3× average, indicating heightened trader interest following the earnings release. Technical indicators are neutral – the 14‑day RSI sits near 50 and the price is just above the 50‑day moving average but below the 200‑day line.

Analyst consensus remains cautiously optimistic. The median price target of $327.5 implies roughly 17% upside from the current level, reflecting expectations that the one‑time Sartorius write‑down will not recur and that cash flow generation will support continued share buybacks. However, investors should monitor the academic funding environment, foreign‑exchange volatility, and any further geopolitical shocks that could depress the clinical‑diagnostics segment. With no dividend and a valuation that still reflects earnings volatility, the stock may appeal primarily to investors seeking exposure to the life‑science tools market and willing to tolerate short‑term earnings swings for long‑term cash‑flow upside.